Voorbeelden van het gebruik van Nelarabine in het Engels en hun vertalingen in het Nederlands
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Computer
-
Ecclesiastic
-
Official/political
-
Programming
Nelarabine is not diluted prior to administration.
Atriance 5 mg/ml solution for infusion Nelarabine.
Nelarabine must not be diluted prior to administration.
Age has no effect on the pharmacokinetics of nelarabine or ara-G.
The effect of nelarabine on fertility in humans is unknown.
What Atriance contains• The active substance of Atriance is nelarabine.
Nelarabine and ara-G are partially eliminated by the kidneys.
Other mechanisms may contribute to the cytotoxic effects of nelarabine.
Nelarabine has not been studied in patients with hepatic impairment.
Intracellular ara-GTP accumulated with repeated administration of nelarabine.
Nelarabine showed in vitro cytotoxicity to monocytes and macrophages.
Gender has no effect on nelarabine or ara-G plasma pharmacokinetics.
Nelarabine has not been studied in individuals with renal impairment.
Severe neurological reactions have been reported with the use of nelarabine.
The excretion of nelarabine in milk has not been studied in animals.
In vitro, T-cells are more sensitive than B-cells to the cytotoxic effects of nelarabine.
It is unknown whether nelarabine or its metabolites are excreted in human breast milk.
Package leaflet: Information for the patient Atriance 5 mg/ml solution for infusion Nelarabine.
It is unknown whether nelarabine or its metabolites are excreted in human breast milk.
Neurotoxicity is the dose limiting toxicity associated with nelarabine therapy see section 4.4.
Nelarabine however, is known to be genotoxic to mammalian cells see section 5.3.
Patients with renal impairment must be closely monitored for toxicities when treated with nelarabine.
Nelarabine was mutagenic to L5178Y/TK mouse lymphoma cells with and without metabolic activation.
Any liquid waste from the preparation of the nelarabine solution for infusion may be flushed with large amounts of water.
Nelarabine is excreted by the kidney to a small extent 5 to 10% of the administered dose.
Concomitant administration may reduce the efficacy of nelarabine and/or change the adverse event profile of either active substance.
Nelarabine and 9-β-D- arabinofuranosylguanine(ara-G)
Plasma ara-G Cmax values generally occurred at the end of the nelarabine infusion and were generally higher than nelarabine Cmax values, suggesting rapid and extensive conversion of nelarabine to ara-G.
Nelarabine at a dose of 1500 mg/m2/day was administered intravenously over two hours on days 1, 3
The effect of race on nelarabine and ara-G pharmacokinetics has not been specifically studied.